Cargando…

Comparison of 3D and 4D robustly optimized proton treatment plans for non-small cell lung cancer patients with tumour motion amplitudes larger than 5 mm

BACKGROUND AND PURPOSE: There is no consensus about an ideal robust optimization (RO) strategy for proton therapy of targets with large intrafractional motion. We investigated the plan robustness of 3D and different 4D RO strategies. MATERIALS AND METHODS: For eight non-small cell lung cancer patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Spautz, Saskia, Haase, Leon, Tschiche, Maria, Makocki, Sebastian, Richter, Christian, Troost, Esther G.C., Stützer, Kristin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338142/
https://www.ncbi.nlm.nih.gov/pubmed/37449022
http://dx.doi.org/10.1016/j.phro.2023.100465
_version_ 1785071565124141056
author Spautz, Saskia
Haase, Leon
Tschiche, Maria
Makocki, Sebastian
Richter, Christian
Troost, Esther G.C.
Stützer, Kristin
author_facet Spautz, Saskia
Haase, Leon
Tschiche, Maria
Makocki, Sebastian
Richter, Christian
Troost, Esther G.C.
Stützer, Kristin
author_sort Spautz, Saskia
collection PubMed
description BACKGROUND AND PURPOSE: There is no consensus about an ideal robust optimization (RO) strategy for proton therapy of targets with large intrafractional motion. We investigated the plan robustness of 3D and different 4D RO strategies. MATERIALS AND METHODS: For eight non-small cell lung cancer patients with clinical target volume (CTV) motion >5 mm, different RO approaches were investigated: 3DRO considering the average CT (AvgCT) with a target density override, 4DRO considering three/all 4DCT phases, and 4DRO considering the AvgCT and three/all 4DCT phases. Robustness against setup/range errors, interplay effects based on breathing and machine log file data for deliveries with/without rescanning, and interfractional anatomical changes were analyzed for target coverage and OAR sparing. RESULTS: All nominal plans fulfilled the clinical requirements with individual CTV coverage differences <2pp; 4DRO without AvgCT generated the most conformal dose distributions. Robustness against setup/range errors was best for 4DRO with AvgCT (18% more passed error scenarios than 3DRO). Interplay effects caused fraction-wise median CTV coverage loss of 3pp and missed maximum dose constraints for heart and esophagus in 18% of scenarios. CTV coverage and OAR sparing fulfilled requirements in all cases when accumulating four interplay scenarios. Interfractional changes caused less target misses for RO with AvgCT compared to 4DRO without AvgCT (≤42%/33% vs. ≥56%/44% failed single/accumulated scenarios). CONCLUSIONS: All RO strategies provided acceptable plans with equally low robustness against interplay effects demanding other mitigation than rescanning to ensure fraction-wise target coverage. 4DRO considering three phases and the AvgCT provided best compromise on planning effort and robustness.
format Online
Article
Text
id pubmed-10338142
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103381422023-07-13 Comparison of 3D and 4D robustly optimized proton treatment plans for non-small cell lung cancer patients with tumour motion amplitudes larger than 5 mm Spautz, Saskia Haase, Leon Tschiche, Maria Makocki, Sebastian Richter, Christian Troost, Esther G.C. Stützer, Kristin Phys Imaging Radiat Oncol Original Research Article BACKGROUND AND PURPOSE: There is no consensus about an ideal robust optimization (RO) strategy for proton therapy of targets with large intrafractional motion. We investigated the plan robustness of 3D and different 4D RO strategies. MATERIALS AND METHODS: For eight non-small cell lung cancer patients with clinical target volume (CTV) motion >5 mm, different RO approaches were investigated: 3DRO considering the average CT (AvgCT) with a target density override, 4DRO considering three/all 4DCT phases, and 4DRO considering the AvgCT and three/all 4DCT phases. Robustness against setup/range errors, interplay effects based on breathing and machine log file data for deliveries with/without rescanning, and interfractional anatomical changes were analyzed for target coverage and OAR sparing. RESULTS: All nominal plans fulfilled the clinical requirements with individual CTV coverage differences <2pp; 4DRO without AvgCT generated the most conformal dose distributions. Robustness against setup/range errors was best for 4DRO with AvgCT (18% more passed error scenarios than 3DRO). Interplay effects caused fraction-wise median CTV coverage loss of 3pp and missed maximum dose constraints for heart and esophagus in 18% of scenarios. CTV coverage and OAR sparing fulfilled requirements in all cases when accumulating four interplay scenarios. Interfractional changes caused less target misses for RO with AvgCT compared to 4DRO without AvgCT (≤42%/33% vs. ≥56%/44% failed single/accumulated scenarios). CONCLUSIONS: All RO strategies provided acceptable plans with equally low robustness against interplay effects demanding other mitigation than rescanning to ensure fraction-wise target coverage. 4DRO considering three phases and the AvgCT provided best compromise on planning effort and robustness. Elsevier 2023-06-24 /pmc/articles/PMC10338142/ /pubmed/37449022 http://dx.doi.org/10.1016/j.phro.2023.100465 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Spautz, Saskia
Haase, Leon
Tschiche, Maria
Makocki, Sebastian
Richter, Christian
Troost, Esther G.C.
Stützer, Kristin
Comparison of 3D and 4D robustly optimized proton treatment plans for non-small cell lung cancer patients with tumour motion amplitudes larger than 5 mm
title Comparison of 3D and 4D robustly optimized proton treatment plans for non-small cell lung cancer patients with tumour motion amplitudes larger than 5 mm
title_full Comparison of 3D and 4D robustly optimized proton treatment plans for non-small cell lung cancer patients with tumour motion amplitudes larger than 5 mm
title_fullStr Comparison of 3D and 4D robustly optimized proton treatment plans for non-small cell lung cancer patients with tumour motion amplitudes larger than 5 mm
title_full_unstemmed Comparison of 3D and 4D robustly optimized proton treatment plans for non-small cell lung cancer patients with tumour motion amplitudes larger than 5 mm
title_short Comparison of 3D and 4D robustly optimized proton treatment plans for non-small cell lung cancer patients with tumour motion amplitudes larger than 5 mm
title_sort comparison of 3d and 4d robustly optimized proton treatment plans for non-small cell lung cancer patients with tumour motion amplitudes larger than 5 mm
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338142/
https://www.ncbi.nlm.nih.gov/pubmed/37449022
http://dx.doi.org/10.1016/j.phro.2023.100465
work_keys_str_mv AT spautzsaskia comparisonof3dand4drobustlyoptimizedprotontreatmentplansfornonsmallcelllungcancerpatientswithtumourmotionamplitudeslargerthan5mm
AT haaseleon comparisonof3dand4drobustlyoptimizedprotontreatmentplansfornonsmallcelllungcancerpatientswithtumourmotionamplitudeslargerthan5mm
AT tschichemaria comparisonof3dand4drobustlyoptimizedprotontreatmentplansfornonsmallcelllungcancerpatientswithtumourmotionamplitudeslargerthan5mm
AT makockisebastian comparisonof3dand4drobustlyoptimizedprotontreatmentplansfornonsmallcelllungcancerpatientswithtumourmotionamplitudeslargerthan5mm
AT richterchristian comparisonof3dand4drobustlyoptimizedprotontreatmentplansfornonsmallcelllungcancerpatientswithtumourmotionamplitudeslargerthan5mm
AT troostesthergc comparisonof3dand4drobustlyoptimizedprotontreatmentplansfornonsmallcelllungcancerpatientswithtumourmotionamplitudeslargerthan5mm
AT stutzerkristin comparisonof3dand4drobustlyoptimizedprotontreatmentplansfornonsmallcelllungcancerpatientswithtumourmotionamplitudeslargerthan5mm